IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Jennison Associates LLC

Jennison Associates LLC trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 46.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 526,688 shares of the company's stock after selling 447,948 shares during the quarter. Jennison Associates LLC owned 0.60% of IDEAYA Biosciences worth $8,627,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in IDYA. CWM LLC increased its position in IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after purchasing an additional 1,814 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $47,000. Signaturefd LLC grew its holdings in IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after acquiring an additional 2,271 shares during the period. Exchange Traded Concepts LLC grew its holdings in IDEAYA Biosciences by 46.4% during the first quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after acquiring an additional 2,112 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its position in IDEAYA Biosciences by 33.2% in the first quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company's stock worth $189,000 after acquiring an additional 2,884 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA traded up $1.20 during trading hours on Thursday, reaching $24.83. 2,176,666 shares of the company traded hands, compared to its average volume of 920,064. The firm's 50-day moving average is $21.35 and its 200-day moving average is $20.33. The stock has a market cap of $2.17 billion, a P/E ratio of -6.92 and a beta of 0.03. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the business earned ($0.53) earnings per share. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on IDYA shares. Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 target price on the stock. TD Cowen began coverage on shares of IDEAYA Biosciences in a report on Tuesday. They set a "buy" rating on the stock. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and lowered their target price for the stock from $57.00 to $30.00 in a research report on Wednesday, July 9th. JPMorgan Chase & Co. increased their target price on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a report on Thursday, May 22nd. Finally, The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price target on the stock in a research note on Thursday, July 10th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $47.55.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.